Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
03/2003
03/13/2003WO2003020949A2 Targeted nucleic acid constructs and uses related thereto
03/13/2003WO2003020889A2 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
03/13/2003WO2003020759A2 A caspase- 8 binding protein, its preparation and use
03/13/2003WO2003020753A1 Peptidic compounds selectively binding to p-selectin
03/13/2003WO2003020751A2 Homing peptides
03/13/2003WO2003020722A1 Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
03/13/2003WO2003020721A1 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases
03/13/2003WO2003020716A1 Piperidine derivatives useful as ccr5 antagonists
03/13/2003WO2003020715A1 Aminopyrrole compounds as antiinflammatory agents
03/13/2003WO2003020703A1 Cyclic amine compound
03/13/2003WO2003020702A2 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
03/13/2003WO2003020700A2 SUBSTITUTED INDENO[1,2-c]ISOQUINOLINE DERIVATIVES AND METHODS OF USE THEREOF
03/13/2003WO2003020325A2 Methods for sterilizing preparations containing albumin
03/13/2003WO2003020320A2 Nanoparticles comprising biologically active tnf which is immobilised on the same
03/13/2003WO2003020309A2 Compound
03/13/2003WO2003020304A2 Inflammation modulatory compound comprising an endomorphin
03/13/2003WO2003020290A1 Therapeutic process for p. aeruginosa infections using macrolide antibiotics
03/13/2003WO2003020287A2 Methods for the treatment of chronic pain anc compositions therefor
03/13/2003WO2003020278A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
03/13/2003WO2003020273A2 Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use
03/13/2003WO2003020269A1 Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
03/13/2003WO2003020261A1 Pharmaceutical composition comprising lumiracoxib
03/13/2003WO2003020253A2 Pharmaceutical compositions for the treatment of asthma
03/13/2003WO2003020213A2 Methods and compositions for treating inflammatory disorders
03/13/2003WO2003020172A1 An implantable and sealable system for unidirectional delivery of therapeutic agents to targeted tissues
03/13/2003WO2003020104A2 Method of treating systemic inflammatory response syndrome
03/13/2003WO2003020037A1 Multivesicular emulsion topical delivery systems
03/13/2003WO2003020005A2 Lp mammalian proteins; related reagents
03/13/2003WO2002100354A3 Pyrrolo[2,3-d]pyrimidine nucleoside analogs
03/13/2003WO2002089796A3 Methods for selective immunomodulation using pimecrolimus
03/13/2003WO2002089743A3 Use of compositions for treating rosacea
03/13/2003WO2002088080A3 Dual inhibitors of pde 7 and pde 4
03/13/2003WO2002087513A3 Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
03/13/2003WO2002078625A3 Therapeutic combinations for cardiovascular and inflammatory indications
03/13/2003WO2002077217A3 Human dual specificity protein phosphatase 7-like protein
03/13/2003WO2002074726A3 Aniline derivatives useful as phosphodiesterase 4 inhibitors
03/13/2003WO2002072543A3 Rxr activating molecules
03/13/2003WO2002068388A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists
03/13/2003WO2002067996A3 Beta-endorphin/crf gene therapy for locally combating pain
03/13/2003WO2002067760A3 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
03/13/2003WO2002053519A3 Hydrophobic polyamine analogs and methods for their use
03/13/2003WO2002052270A3 Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
03/13/2003WO2002050286A3 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
03/13/2003WO2002050019A3 Diamines as modulators of chemokine receptor activity
03/13/2003WO2002046412A3 Regulation of angiogenesis with zinc finger proteins
03/13/2003WO2002046191A3 Urea substituted imidazoquinoline ethers
03/13/2003WO2002046188A3 Amido ether substituted imidazoquinolines
03/13/2003WO2002045703A3 Mixtures or organic compounds for the treatmentof airway diseases
03/13/2003WO2002044128A3 Salicylate analogs as interleukin-4 antagonists
03/13/2003WO2002042332A3 Truncated cd200
03/13/2003WO2002042319A3 2-substituted estrogens as antiangiogenic agents
03/13/2003WO2002038140A3 Therapeutic uses for ip3 receptor-mediated calcium channel modulators
03/13/2003WO2002036553A3 Substituted alkanoic acids
03/13/2003WO2002031511A3 Modulation of ligand binding/enzymatic activity of alpha beta proteins
03/13/2003WO2002024194A3 Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
03/13/2003WO2002022563A1 Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient
03/13/2003WO2002022151A3 Use of glp-1 and flp-2 peptides for treatment of bone disorders
03/13/2003WO2002013866A3 Stimulating neutrophil function to treat inflammatory bowel disease
03/13/2003WO2001082911A3 TREATMENT OF PATHOLOGICAL CONDITIONS INFLUENCED BY THE ACTION OF MATRIX METALLOPROTEINASES (MMPs) USING CLIOQUINOL
03/13/2003US20030050461 Protein for use in the diagnosis, prevention and treatment of metabolic, developmental, nutrient transport and cell proliferation disorders
03/13/2003US20030050460 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of cardiovascular and bone disorders
03/13/2003US20030050342 Administering an effective amount of calcium L-threonate to a subject in need of such prevention or treatment
03/13/2003US20030050337 Polymorphic B Form of 3-(cyclopropylmethoxy)-4-[4(methylsulfonyl)phenyl]-5,5- dimethyl-5H-furan-2-one
03/13/2003US20030050329 Synergistic combination comprising roflumilast and a PDE-3 inhibitor
03/13/2003US20030050314 Treating bone disorder caused by osteoclasts, tumor growth and tumor metastasis, prophylaxis of cardiovascular disorders, nephropathies or retinopathies
03/13/2003US20030050310 Hydroxamic acid derivatives as proteinase inhibitors
03/13/2003US20030050309 A gelatinase inhibitor for modulating the activity of a dopamine, serotonin, or norepinephrine receptor or transporter
03/13/2003US20030050298 A sulfonamide substituted diphenyl thiourea compounds treating a chemokine mediated disease
03/13/2003US20030050278 Agent and food for inhibiting IgE antibody
03/13/2003US20030050272 Purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase nucleic acids and polypeptides
03/13/2003US20030050265 A compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding transforming growth factor-beta 2
03/13/2003US20030050250 Administering an aromatic dipeptide derivative with a chemotherapeutic agent to treat tumor metastasis, solid tumor growth, angiogenesis and other neoplasia diseases
03/13/2003US20030050249 Complexes of alpha-6 integrin subunits with small peptides and methods for treating indications resulting from modulation of integrin-mediated responses by altering signal transduction
03/13/2003US20030050242 Protein polymerization inhibitors and methods of use
03/13/2003US20030050235 Detecting the activity of orphan G Protein Receptor 86 by incubating a sample comprising GPR86 and adenosine diphosphate (ADP) under binding conditions for both and detecting a second messanger; screening for a modulator
03/13/2003US20030050234 Conotoxin peptide extracted from the venom of a marine snail, Conus magnus (cono=cone); disorders associated with voltage gated sodium ion channel; neuromuscular blocking agents; local anesthetics; neuroprotective agents; analgesics
03/13/2003US20030049713 Evaluating modulator of kallikrein generation; obtain prekallikrein mixture, incubate with kininogen, phosphate and zinc ions and modulator, monitor adjustment in generation of kallikrein
03/13/2003US20030049643 G protein-coupled receptors for use in the treatment of cardiovascular, nervous system, angina pectoris, inflamatory bowel, allergies and gastrointestinal disorders
03/13/2003US20030049609 Viral proteins capable of binding LAR
03/13/2003US20030049281 Topical emulsion; quaternary ammonium salt emulsifier
03/13/2003US20030049271 Diagnosis, therapy of bacteria infections
03/13/2003US20030049261 Administering chitinase inhibitor
03/13/2003US20030049260 Method of improving cognitive function
03/13/2003US20030049259 Control of lymphocyte localization by LEEP-CAM activity
03/13/2003US20030049255 Interleukin-1 receptors in the treatment of diseases
03/13/2003US20030049208 For delivering a medicant; product includes a coating having a medicament or agent; bioavailabilty; chewing gum product that releases caffiene for improved performance
03/13/2003US20030049203 Targeted nucleic acid constructs and uses related thereto
03/13/2003CA2459796A1 Homing peptides
03/13/2003CA2459413A1 Methods for sterilizing preparations containing albumin
03/13/2003CA2459161A1 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
03/13/2003CA2459136A1 A caspase-8 binding protein, its preparation and use
03/13/2003CA2458876A1 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
03/13/2003CA2458808A1 Aminopyrrole compounds as antiinflammatory agents
03/13/2003CA2458780A1 Targeted nucleic acid constructs and uses related thereto
03/13/2003CA2458682A1 Nanoparticles comprising biologically active tnf which is immobilised on the same
03/13/2003CA2458677A1 Methods and compositions for treating inflammatory disorders
03/13/2003CA2457926A1 Pharmaceutical compositions for the treatment of asthma
03/13/2003CA2457861A1 Piperidine derivatives useful as ccr5 antagonists
03/13/2003CA2457534A1 Substituted indeno[1,2-c]isoquinoline derivatives and methods of use thereof
03/13/2003CA2422135A1 Urea derivatives and adhesion molecule inhibitors containing the same as effective ingredients
1 ... 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 ... 1272